List view / Grid view
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
The Government of Malawi has launched the world’s first malaria vaccine which will be made available to children up to two years of age.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation...
The artemisinin-based combination therapy (ACT), pyronaridine-artesunate, has been shown to be as effective in treating malaria as other drugs...
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
Scientists in California have undertaken studies that have demonstrated the effectiveness of a sophisticated algorithm in preventing the spread of infectious diseases. The application of AI allows authorities to identify the best use of resources and highlight subtle interaction points that might otherwise be missed.
Researchers have shown that two different compounds can safely and effectively be added to treatment regimens to block the transmission of the most common form of malaria...
An international research team has conducted successful phase II clinical tests of a new anti-malaria medication...
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of the malaria parasite that have grown resistant to one of the currently used drugs...
Chloroquine and hydroxychloroquine could make cancer treatments more effective...
Researchers have published two systematic reviews revealing the safety of mefloquine for preventing malaria in travellers...
New research demonstrates that the malaria treatment, artemisinin can now be rapidly produced by genetically engineered moss at an industrial scale...
A patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite has been launched...
17 May 2017 | By Niamh Marriott, Junior Editor
Study shows how a mixture of chitin and silver nanoparticles inhibits growth of mosquito larvae...
